With use of an ELISA employing purified recombinant HOXA7 protein, Naora et al. [15] detected anti-HOXA7 AAbs in the sera of 1/24 (4.1%) patients with poorly differentiated ovarian serous carcinoma, 16/24 (66.6%) patients with well-to moderately differentiated ovarian serous carcinoma, 13/19 (68.4%) patients with benign ovarian serous cystadenoma, and 0/30 (0%) healthy women. Here, HOXA7 is linked to ovarian serous carcinoma.